NO20022065L - Terapeutisk anvendelse - Google Patents

Terapeutisk anvendelse

Info

Publication number
NO20022065L
NO20022065L NO20022065A NO20022065A NO20022065L NO 20022065 L NO20022065 L NO 20022065L NO 20022065 A NO20022065 A NO 20022065A NO 20022065 A NO20022065 A NO 20022065A NO 20022065 L NO20022065 L NO 20022065L
Authority
NO
Norway
Prior art keywords
therapeutic use
patient
chemoprevention
onset
effective amount
Prior art date
Application number
NO20022065A
Other languages
English (en)
Other versions
NO323206B1 (no
NO20022065D0 (no
Inventor
Nigel James Bundred
Original Assignee
Univ Manchester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Manchester filed Critical Univ Manchester
Publication of NO20022065D0 publication Critical patent/NO20022065D0/no
Publication of NO20022065L publication Critical patent/NO20022065L/no
Publication of NO323206B1 publication Critical patent/NO323206B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20022065A 1999-11-02 2002-04-30 Anvendelse av EGFR-tyrosinkinase-inhibitor for fremstilling av et medikament, og et medisinsk testsett som omfatter en EGFR-tyrosinkinase-inhibitor NO323206B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9925958.2A GB9925958D0 (en) 1999-11-02 1999-11-02 Therapeutic use
PCT/GB2000/004190 WO2001032155A2 (en) 1999-11-02 2000-11-01 Use of egfr tyrosine kinase inhibitors for treating breast cancer

Publications (3)

Publication Number Publication Date
NO20022065D0 NO20022065D0 (no) 2002-04-30
NO20022065L true NO20022065L (no) 2002-06-24
NO323206B1 NO323206B1 (no) 2007-01-22

Family

ID=10863835

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20022065A NO323206B1 (no) 1999-11-02 2002-04-30 Anvendelse av EGFR-tyrosinkinase-inhibitor for fremstilling av et medikament, og et medisinsk testsett som omfatter en EGFR-tyrosinkinase-inhibitor

Country Status (21)

Country Link
US (1) US7553815B1 (no)
EP (1) EP1272188B1 (no)
JP (1) JP2003513035A (no)
KR (1) KR100785359B1 (no)
CN (1) CN1197577C (no)
AT (1) ATE339957T1 (no)
AU (1) AU779190B2 (no)
BR (1) BR0015194A (no)
CA (1) CA2389411C (no)
CY (1) CY1106285T1 (no)
DE (1) DE60030889T2 (no)
DK (1) DK1272188T3 (no)
ES (1) ES2275556T3 (no)
GB (1) GB9925958D0 (no)
IL (1) IL149176A0 (no)
MX (1) MXPA02004272A (no)
NO (1) NO323206B1 (no)
NZ (1) NZ518696A (no)
PT (1) PT1272188E (no)
WO (1) WO2001032155A2 (no)
ZA (1) ZA200203431B (no)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2331646T3 (es) 2000-05-19 2010-01-12 Genentech, Inc. Ensayo para la deteccion de genes para mejorar la probabilidad de una respuesta eficaz a una terapia contra el cancer basada en antagonistas de erbb.
EP1408980A4 (en) 2001-06-21 2004-10-20 Ariad Pharma Inc NEW QUINAZOLINES AND THEIR USE
US6872715B2 (en) * 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
US20050038048A1 (en) * 2001-10-29 2005-02-17 Ball Howard Ashley Use of 7h-pyrrollo{2,3-d}pyrimidine derivatives in the treatment of solid tumor diseases
DK2305255T3 (da) * 2001-12-03 2012-12-10 Bayer Healthcare Llc Arylurinstofforbindelser i kombination med andre cytostatiske eller cytotoksiske midler til behandling af humane cancere
US7078409B2 (en) 2002-03-28 2006-07-18 Beta Pharma, Inc. Fused quinazoline derivatives useful as tyrosine kinase inhibitors
EP1837025A3 (en) * 2002-06-05 2007-12-19 Cedars-Sinai Medical Center Method of treating cancer using kinase inhibitors
WO2005017493A2 (en) * 2003-08-15 2005-02-24 Smithkline Beecham Corporation Biomarkers in cancer
EP1667992B1 (en) 2003-09-19 2007-01-24 Astrazeneca AB Quinazoline derivatives
WO2005039588A2 (en) * 2003-10-22 2005-05-06 Novartis Ag Methods for determining the risk of developing liver and lung toxicity
US7701341B2 (en) * 2004-09-01 2010-04-20 Microsoft Corporation Device service provider interface
PL1846030T3 (pl) 2005-01-21 2019-05-31 Genentech Inc Ustalone dawkowanie przeciwciał her
UA95902C2 (ru) 2005-02-23 2011-09-26 Дженентек, Инк. Способ увеличения времени развития заболевания или выживаемости у раковых пациентов
CN101003514A (zh) * 2006-01-20 2007-07-25 上海艾力斯医药科技有限公司 喹唑啉衍生物、其制备方法及用途
CN101415422B (zh) 2006-02-09 2012-11-07 第一三共株式会社 抗癌药用组合物
CN1899616A (zh) * 2006-07-20 2007-01-24 中国人民解放军军事医学科学院生物工程研究所 非受体酪氨酸激酶c－Abl特异性抑制剂的新用途
NZ578824A (en) 2007-03-02 2012-03-30 Genentech Inc Predicting response to a her dimerisation inhibitor based on low her3 expression
EP2592156B1 (en) 2007-06-08 2016-04-20 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
US8673876B2 (en) 2009-03-11 2014-03-18 Ardea Biosciences Inc. Pharmaceutical combinations for treatment of specific cancers
MA33198B1 (fr) 2009-03-20 2012-04-02 Genentech Inc Anticorps anti-her di-spécifiques
JP5705836B2 (ja) 2009-05-29 2015-04-22 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｈｅｒ２を発現する胃癌患者のｈｅｒ２シグナル伝達のためのモジュレーター
MX2012008958A (es) 2010-02-18 2012-08-23 Genentech Inc Antagonista de neurogulina y usos de los mismos para el tratamiento contra el cancer.
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
EP2643353A1 (en) 2010-11-24 2013-10-02 Novartis AG Multispecific molecules
WO2012085111A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
MX2014001766A (es) 2011-08-17 2014-05-01 Genentech Inc Anticuerpos de neuregulina y sus usos.
US9327023B2 (en) 2011-10-25 2016-05-03 The Regents Of The University Of Michigan HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
WO2013081645A2 (en) 2011-11-30 2013-06-06 Genentech, Inc. Erbb3 mutations in cancer
WO2013083810A1 (en) 2011-12-09 2013-06-13 F. Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
CN104220457A (zh) 2012-03-27 2014-12-17 霍夫曼-拉罗奇有限公司 涉及her3抑制剂的诊断和治疗
RU2692773C2 (ru) 2012-11-30 2019-06-27 Ф.Хоффманн-Ля Рош Аг Идентификация пациентов, нуждающихся в совместной терапии с использованием ингибитора pd-l1
WO2017194554A1 (en) 2016-05-10 2017-11-16 Inserm (Institut National De La Sante Et De La Recherche Medicale) Combinations therapies for the treatment of cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
US5795910A (en) * 1994-10-28 1998-08-18 Cor Therapeutics, Inc. Method and compositions for inhibiting protein kinases
DE69536015D1 (de) * 1995-03-30 2009-12-10 Pfizer Prod Inc Chinazolinone Derivate
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508565D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
WO1996040142A1 (en) * 1995-06-07 1996-12-19 Pfizer Inc. Heterocyclic ring-fused pyrimidine derivatives
BR9609617B1 (pt) * 1995-07-06 2010-07-27 derivados de 7h-pirrol[2,3-d]pirimidina, e composição farmacêutica.
WO1999060023A1 (en) * 1998-05-15 1999-11-25 Imclone Systems Incorporated Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases
WO2008026150A1 (en) 2006-08-28 2008-03-06 Koninklijke Philips Electronics N.V. Method and apparatus for image enhancement

Also Published As

Publication number Publication date
DK1272188T3 (da) 2007-01-29
DE60030889T2 (de) 2007-04-05
EP1272188A2 (en) 2003-01-08
KR100785359B1 (ko) 2007-12-18
US7553815B1 (en) 2009-06-30
JP2003513035A (ja) 2003-04-08
MXPA02004272A (es) 2003-08-20
WO2001032155A3 (en) 2002-05-10
IL149176A0 (en) 2002-11-10
DE60030889D1 (de) 2006-11-02
EP1272188B1 (en) 2006-09-20
ES2275556T3 (es) 2007-06-16
CA2389411A1 (en) 2001-05-10
AU1155901A (en) 2001-05-14
ZA200203431B (en) 2003-02-26
CA2389411C (en) 2009-09-01
NO323206B1 (no) 2007-01-22
AU779190B2 (en) 2005-01-13
CN1387437A (zh) 2002-12-25
CN1197577C (zh) 2005-04-20
WO2001032155A2 (en) 2001-05-10
NZ518696A (en) 2004-12-24
KR20020064306A (ko) 2002-08-07
CY1106285T1 (el) 2011-10-12
GB9925958D0 (en) 1999-12-29
NO20022065D0 (no) 2002-04-30
PT1272188E (pt) 2007-01-31
ATE339957T1 (de) 2006-10-15
BR0015194A (pt) 2002-06-18

Similar Documents

Publication Publication Date Title
NO20022065D0 (no) Terapeutisk anvendelse
TR200201442T2 (tr) Ağrı hafifletme, kemik kanseri terapisi ve kemik yüzeyinin sağlıklı tutulması için kireçlenmiş hedef dokulara yönelik radyum-223 hazırlanması ve kullanımı.
EG25822A (en) Quinolinyl-pyrrolopyrazoles
ATE307601T1 (de) Brustkrebsbehandlung mittels natürlicher ätherischer öle
CY1112753T1 (el) Θεραπευτικη αγωγη καρκινων του ανθρωπινου σωματος με τη χρηση toy ετ743
MY138059A (en) Use of ikb-kinase inhibitors in pain therapy
NO20032027L (no) Effektive antitumorbehandlinger
PT1390371E (pt) Oxazolo- e furopirimidinas e sua utilizacao em medicamentos contra tumores
MX2007006927A (es) Combinacion de inhibidor de tirosina cinasa y her-2/neu para terapia de cancer.
SE0300098D0 (sv) Use of cyclin D1 inhibitors
HK1080733A1 (en) Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol
DE60111515D1 (de) Kombinationstherapie mit keratinozyten-wachstumfaktor und ein epidermis-wachstumfaktor inhibitor
TR200101693T2 (tr) Lemfotoksin (LT) sentezlenme yolunun inhibitörleri kullanılarak foliküler lemfomaların tedavisi.
DK1276501T5 (da) Fremgangsmåde til behandling af tumorer under anvendelse af fotodynamisk terapi
SE9802209D0 (sv) Novel compounds
EA200200853A1 (ru) Применение 2-метилтиазолидин-3,3-дикарбоновой кислоты (2-мтдк) и/или ее физиологически совместимых солей для лечения и/или предупреждения рака
HUP0301276A2 (hu) Kombinációs terápia ösztrogénérzékeny betegségek kezelésére
IT1320192B1 (it) Composizione terapeutica per la cura della psoriasi.
DE60234995D1 (de) Tatakrebs
ITPD20020003A1 (it) Biomateriali a base di acido ialuronico come terapia anti-angiogenicanella cura dei tumori.
DE60316927D1 (de) Verwendung von devazepide als schmerzmittel
EA200600987A1 (ru) Применение сирамезина в лечении злокачественных опухолей

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees